HeartSciences (HSCSW) Cash & Equivalents (2022 - 2026)

HeartSciences (HSCSW) has 5 years of Cash & Equivalents data on file, last reported at $3.4 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Equivalents rose 30.83% year-over-year to $3.4 million; the trailing twelve-month figure through Jan 2026 stood at $3.4 million (up 30.83% YoY), and the FY2025 full-year result was $1.1 million, down 81.07% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $3.4 million, up from $2.0 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $7.1 million in Q1 2024 and bottomed at $100144.0 in Q4 2023.
• The 5-year median for Cash & Equivalents is $2.7 million (2025), against an average of $2.9 million.
• The widest annual swing landed in 2023, when Cash & Equivalents plunged 96.74%; it then surged 3946.29% in 2024.
• A 5-year view of Cash & Equivalents shows it stood at $3.1 million in 2022, then slumped by 96.74% to $100144.0 in 2023, then soared by 3946.29% to $4.1 million in 2024, then tumbled by 51.85% to $2.0 million in 2025, then soared by 74.11% to $3.4 million in 2026.
• The last three Cash & Equivalents figures came in at $3.4 million (Q1 2026), $2.0 million (Q4 2025), and $2.8 million (Q3 2025), per Business Quant data.

Peer Comparison